BSN: HCV Drug Discovery

   Speakers
   --------

   N/A

   It is an exciting time for the field of HCV antivirals. Viral protease
   and polymerase inhibitors are in late stage clinical trials, as are
   combinations of them, suggesting an interferon-free drug cocktail to
   treat HCV may one day be possible. Progress is also being made on
   small molecule drug candidates that inhibit host proteins involved in
   the maturation/processing of HCV particles.

Event Sponsors

Cambridge Healthtech Associates

Schedule of Presentations:

Wednesday, April 28, 2010
12:30:00	Registration
13:25:00	Inhibiting HCV Polymerase (NS5B)
13:30:00	Chairperson's Opening Remarks
13:40:00	Structure-Based Design of Non-Nucleoside NS5B Inhibitors for the Treatment of HCV	Francisco Talamas
14:10:00	PSI-7851: Development of a Nucleotide Prodrug for the Treatment of HCV	Michael J. Sofia
14:40:00	Novel Phosphoramidate HCV NS5b Inhibitors	Joseph M Patti
15:10:00	Sponsored Presentations (Opportunity Available)
15:40:00	Networking Refreshment Break, Poster and Exhibit Viewing
16:15:00	Inhibiting HCV NS5A
16:20:00	The Identification and Optimization of HCV Replicon Inhibitors Characterised by NS5A Specific Mutations	Stuart Cockerill
16:50:00	Discovery and Characterization of PPI-461, a Potent and Selective HCV NS5A Inhibitor with Broad-Spectrum Coverage of all HCV Genotypes	Richard Colonno
17:20:00	Break-Out Discussions
18:30:00	End of Day
Thursday, April 29, 2010
07:30:00	Breakfast Workshop Presentation (Sponsorship Opportunity Available) or Morning Coffee
08:10:00	Inhibiting HCV Protease
08:15:00	Chairperson's Opening Remarks
08:20:00	KEYNOTE Telaprevir: Discovery, Homologues and Clinical Update	Youssef Bennani
09:00:00	Protein Silencing of Hepatitis C Virus NS3/4A Protease in vitro and in vivo With AVL-181	Juswinder Singh
09:30:00	Recent Developments in HCV NS3/4A Protease Inhibitor	Nigel Liverton
10:00:00	Networking Coffee Break, Poster and Exhibit Viewing
10:45:00	Boron and Non-Boron-Based HCV NS3/4 Protease InIhibitors: Discovery of a Novel Motif Possessing High Potency against PI-Resistant Mutants	Wieslaw Kazmierski
11:15:00	HCV-Protease Inhibitors: Current and the Next Generation	Atul Agarwal
11:45:00	TMC435 Clinical Update and In Vitro Combination	Kenny Simmen
12:15:00	Sponsored Presentation (Opportunity Available)
12:30:00	Walk and Talk Luncheon in the Exhibit Hall (Last Chance for Poster and Exhibit Viewing)
13:50:00	New Viral Targets
13:55:00	Chairperson's Remarks
14:00:00	Discovery of Potent and Mechanistically Distinct Inhibitors of HCV Entry	William C. Olson
14:30:00	Core Protein: A New Target for the Development of Novel Small Molecule Inhibitors of HCV	A. Donny Strosberg
15:00:00	Networking Refreshment Break
15:15:00	Targeting The Host
15:20:00	Development of SR-B1 Modulators as HCV Entry Inhibitors	Jeffrey McKelvy
15:50:00	Targeting TLR7	James Appleman
16:20:00	Mechanism of HCV Resistance to Cyclophilin Inhibitors	Hengli Tang
16:50:00	End of Conference

BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.